traN Antibody

Basic Research Questions

• What is Anti-Tissue Transglutaminase Antibody Testing and How is it Applied in Research?

  Anti-tissue transglutaminase antibody testing (tTG-IgA) is primarily used to diagnose celiac disease, an autoimmune disorder where the body attacks itself. In research settings, this test helps establish disease models and monitor treatment efficacy.

  Methodology:

  • The test measures IgA antibodies that target tissue transglutaminase, an enzyme that repairs tissue damage

  • Higher levels of these antibodies indicate potential celiac disease

  • Research applications include:

    • Monitoring disease progression through quantitative antibody titer measurements

    • Evaluating gluten sensitivity in experimental models

    • Assessing autoimmune responses in various conditions

  Blood tests showing elevated anti-tissue transglutaminase antibodies help researchers identify celiac disease biomarkers and develop new therapeutic approaches .

• How Do Trans-Chromosomic Mice Contribute to Antibody Research?

  Trans-chromosomic (TC) mice are engineered to carry human immunoglobulin loci on engineered chromosomes, enabling them to produce human antibodies.

  Methodology:

  • TC-mAb mice stably maintain mouse-derived engineered chromosomes containing entire human Ig heavy and kappa chain loci in a mouse Ig-knockout background

  • High-throughput DNA sequencing confirms that these mice recapitulate the human Ig repertoire, including variable gene usage patterns

  • Despite slightly altered B cell development and delayed immune responses, TC-mAb mice develop more antigen-specific plasmablast and plasma cell subsets than wild-type mice

  • This leads to more efficient hybridoma production for generating human antibodies

  These mice provide an invaluable platform for obtaining fully human therapeutic antibodies and serve as models for understanding human Ig repertoire formation mechanisms .

• How Do Neutralizing Antibodies Differ from Binding Antibodies in Functionality?

  Neutralizing antibodies (nAbs) have the specific ability to block pathogen functionality, while binding antibodies simply attach to antigens without necessarily inhibiting their activity.

  Methodology for Detection:

  • Traditional assays for neutralizing antibodies often require viral culture in biosafety level 3 laboratories

  • Newer proximity-based luciferase assays offer rapid (<30 min), cell-free alternatives

  • These assays exploit the mechanism of potent SARS-CoV-2 nAbs, which function by blocking binding between viral proteins and receptors like ACE2

  • The method correlates well with conventional pseudotyped virus neutralization assays

  This approach is particularly valuable for testing patients with HIV on antiretroviral therapies, which can interfere with conventional pseudotyped virus assays .

• What Are Bispecific Antibodies and How Do They Differ from Conventional Antibodies?

  Bispecific antibodies (bsAbs) are engineered antibodies that simultaneously bind to two different antigens through two distinct antigen-binding domains, unlike conventional monoclonal antibodies that target only one antigen.

  Key Characteristics:

  • They can harness a patient's immune system to recognize and kill cancer cells

  • T cell engagers are a type of bispecific antibody that bind to both T cells and cancer cells

  • Unlike CAR-T cell treatments (which require T cell harvesting), bispecific antibodies work with the patient's own T cells already circulating in the body

  • They are typically created entirely in laboratories rather than derived from patient cells

  Bispecific antibodies have shown promise in clinical trials by offering patients long remissions with manageable side effects and are more practical for patients to receive in clinical settings without lengthy hospital stays .

Advanced Research Questions

• What Methodologies Are Used for Creating Bispecific Antibodies and What Are Their Limitations?

  Creating bispecific antibodies presents significant engineering challenges, particularly regarding the chain-pairing problem where heavy and light chains must form correct pairings.

  Methodological Approaches:

  • Intein-mediated protein trans-splicing for IgG-Fab2-type bispecific antibodies:

    • Separate expression and purification of the IgG part and Fab part circumvents chain-pairing issues

    • Deletion of glycosylation residues can improve reaction yield and reduce side reactions

    • Final products demonstrate target binding activity and cytotoxicity mediated by activated T cells

  Component	Function	Challenge
  IgG structure	Provides Fc-mediated effector functions	Maintaining stability
  Additional Fab regions	Provide binding to second target	Correct orientation
  Protein ligation sites	Connect components	Minimizing side reactions

  This approach expands bispecific antibody production methods, although optimization is needed to improve production efficiency and reduce manufacturing complexity .

• How Can Deep Learning Be Applied to Antibody Design?

  Deep learning approaches are revolutionizing antibody design by enabling the generation of novel antibody sequences with desirable properties.

  Methodological Framework:

  • Generative adversarial networks (GANs) can create libraries of highly human antibody variable regions

  • In one study, 51 in-silico generated antibody sequences were validated by two independent laboratories

  • All generated antibody sequences expressed successfully in mammalian cells and could be purified in sufficient quantities

  • Biophysical properties of generated antibodies were compared with existing therapeutic antibodies:

    • Production metrics (titer and purity) were actually higher for GAN-generated antibodies

    • Thermal stability distributions were nearly identical (p-value: 0.983)

    • Hydrophobicity properties were highly similar between generated and existing antibodies

  This demonstrates that deep learning can produce high-quality antibody candidates with experimentally verifiable properties comparable or even superior to existing therapeutic antibodies .

• How Do Light Chain Framework Regions Impact Antibody Performance?

  Light chain framework regions, often overlooked in antibody engineering, can significantly impact antibody performance, target binding, and manufacturing yield.

  Experimental Evidence:

  • Study findings from A*STAR research:

    • When two amino acids in the framework region of trastuzumab's light chain were deleted:

      • Single deletion led to reduced antibody secretion but minimal impact on target binding

      • Double deletion significantly decreased both antibody production and Her2 binding

    • Structural modeling revealed:

      • Deletions impaired interaction between the antibody and proteins used for purification

      • Changes affected affinity for the target antigen (Her2)

  These findings indicate that light chain framework regions impact key factors of therapeutic antibodies even at sites not directly involved in binding or purification. This supports a holistic approach to antibody engineering that considers the antibody as a whole rather than as separate components .

• What Approaches Are Used to Optimize Antibody Drug Conjugate Dosing for Clinical Translation?

  Translating antibody drug conjugate (ADC) dosing from preclinical models to clinical applications requires careful consideration of multiple factors to predict efficacy and toxicity.

  Methodological Approaches:

  Approach	Principle	Application
  mg/kg dosing	Matches maximum tissue penetration	Ensures similar cells per tumor volume reached
  NHP toxicity data	Clinical MTDs are 2-6× lower than NHP HNSTD	Predicts human tolerability
  Payload considerations	Similar payload mass tolerated whether free or conjugated	Informs payload selection

  Key Findings:

  • Current approved ADCs for solid tumors can show substantial efficacy in some mouse models

  • Matching mg/kg dosing in mice matches the maximum tissue penetration in the clinic

  • Clinical MTDs (maximum tolerated doses) are typically two- to six-fold lower than cynomolgus monkey HNSTDs (highest non-severely toxic doses)

  • Different formats using the same antibody and payload can yield different clinical outcomes based on drug-to-antibody ratio and antibody dosing

  These findings support that matching mg/kg dosing rather than AUC is more predictive of clinical efficacy and tissue penetration from preclinical models .

• How Do Disease-Modifying Antirheumatic Drugs (DMARDs) Affect COVID-19 Vaccine Antibody Response?

  Patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapies may have altered antibody responses to COVID-19 vaccines, requiring specific vaccination strategies.

  Methodological Approach:

  • A multicentre three-arm randomized controlled trial compared:

    • Patients continuing DMARD therapy after vaccination

    • Patients temporarily withholding DMARD therapy for 1-2 weeks after first dose

    • Control subjects without IMID or DMARD therapy

  • Measured SARS-CoV-2 IgG against S1/S2 proteins at:

    • Baseline

    • 3-4 weeks post first vaccination

    • 4 weeks post second vaccination

  Key Findings:

  • After first dose:

    • AZ vaccine: Only 27.3% seroconversion in continue group vs. 79.2% in controls

    • Pfizer vaccine: 64.58% seroconversion in continue group vs. 100% in controls

    • Withholding therapy improved rates to 67.7% (AZ) and 84.1% (Pfizer)

  • After second dose (all continuing therapy):

    • Slightly lower seroconversion rates but comparable antibody titers for most DMARDs

    • Targeted synthetic DMARDs showed significantly lower antibody titers (12.88 vs. 79.49 U/mL)

  This research demonstrates that while initial antibody responses are lower with DMARD therapy, final responses after two doses are excellent regardless of temporary withholding, except for patients on tsDMARDs where withholding is recommended .

• What Data Mining Approaches Are Used for Identifying Antibody Sequences in Proteomic Samples?

  Data mining of antibody sequences enables the identification of antibody peptides in complex biological samples through specialized database searches in bottom-up mass spectrometry.

  Methodological Workflow:

  1. Collection of antibody sequences from the Observed Antibody Space database (OAS)

     • Downloaded 30,966,193 heavy-chain antibody sequences related to SARS-CoV-2

  2. Filtering sequences against human proteins from UniProt

     • Removed peptides present in UniProt database

     • Obtained 18,419,969 distinct peptide sequences unique to antibodies

  3. Database creation and optimization

     • Selected most common peptides present in highest number of antibodies

     • Created six databases of different sizes (DB1-6) containing 10² to 10⁷ most common peptides

  4. Mass spectrometry database searches

     • Applied optimized database to search for antibody peptides in complex samples

     • Focused on peptides in the most variable region (CDR-H3) of antibody heavy chains

  This approach successfully identified antibody peptides, including those from complementarity-determining regions (CDR-H3), which were overrepresented in SARS-CoV-2 samples compared to healthy controls, enabling differentiation between infected and healthy samples .